Over several years, Cecilia was bounced from doctor to doctor until she found someone who finally listened to her concerns and properly diagnosed her with primary biliary cholangitis (#PBC). Ensuring patient voices are heard and understood is a critical aspect of healthcare, and especially important when diagnosing and managing #rarediseases. Watch Cecilia recount her experience with PBC.
Intercept Pharmaceuticals
Pharmaceutical Manufacturing
Morristown, New Jersey 63,179 followers
Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.
About us
We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.
- Website
-
http://www.interceptpharma.com
External link for Intercept Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Morristown, New Jersey
- Type
- Public Company
- Founded
- 2002
- Specialties
- Non-viral Liver Diseases, Rare Diseases, Biotechnology, and Innovation
Locations
-
Primary
Get directions
305 Madison Ave
Morristown, New Jersey 07960, US
-
Get directions
4760 Eastgate Mall
San Diego, CA 92121, US
-
Get directions
2 Pancras Square
Kings Cross
London, N1C 4AG, GB
Employees at Intercept Pharmaceuticals
-
Janet Lewis
-
William Wallace
Chief Information Officer, at Intercept Pharmaceuticals Inc.
-
Grady Mateen
Rare Disease Therapeutic Business Specialist at Intercept Pharmaceuticals | 20+ years in the Pharmaceutical Industry | Territory Turnaround…
-
Arash Thranian, PhD., MBA
Director, Field Medical, Medical Science Liaison at Intercept Pharmaceuticals
Updates
-
Intercept Pharmaceuticals reposted this
Had a great time at the EASL | The Home of Hepatology Annual Congress in Milan earlier this month! And honored to have the chance to present a poster on behalf of my colleagues for our research into liver biochemistries in primary biliary cholangitis. #EASL2024 #liver
-
-
It was great to connect in person with the global liver health community at this year’s #EASLCongress in Milan! Thank you to everyone who met with us.
-
-
Join us in wishing the Global Liver Institute a very happy 10th anniversary! We had a great time celebrating the past decade in Milan, and we can’t wait to see what the future may bring.
-
-
We’re pleased to announce late breaking data at #EASLCongress from our Phase 2 combination study in primary biliary cholangitis (#PBC). Learn more: https://lnkd.in/eVqQ-ypf
-
We’re proud to support the American Liver Foundation’s Liver Life Walk. Our team had a great time in NJ walking alongside the community!
-
-
We’re looking forward to engaging with the #liver community at #EASLCongress 2024 in Milan, where we’re presenting our latest research in #PBC. We hope to see you there!
-
-
Will you be at #EASLCongress 2024? Learn more about data being shared from our landmark Phase 3 POISE study in primary biliary cholangitis (#PBC): https://lnkd.in/eHKPV-RN
-
-
We’re excited to announce the acceptance of multiple abstracts at #EASLCongress 2024, including 7 posters on #PBC. Learn more: https://lnkd.in/eKk3TCnm
-
-
Today we celebrate the 8th anniversary of the approval of our medicine for primary biliary cholangitis (PBC). As we reflect on this remarkable journey of nearly a decade, we are grateful for the opportunity to support those living with #PBC, whose strength and resilience inspire us every day.
-
Similar pages
Browse jobs
Stock
ICPT
NASDAQ
20 minutes delay
$19.00
- Open
- 19
- Low
- 18.98
- High
- 19.01
Data from Refinitiv
See more info on